ENTO - Wutah pendapatan taun lumaku enterothera.com

Logo perusahaan publik Entero Therapeutics Inc. (ENTO)

Entero Therapeutics, Inc. (ENTO) develops enzyme-based treatments to combat celiac disease, establishing a comprehensive therapy system for digestive pathologies. However, the lack of recurring revenue and the costs associated with clinical trials are creating a liquidity deficit. The relative change in trailing twelve-month revenue compared to the same period last year confirms these data, with the current level standing at 0.00, reflecting the reaction of commercial volumes to external market shifts.

ENTO - Wutah dodolan YoY sajrone rolas wulan kepungkur Entero Therapeutics ing rentang 23.11.2025 - 01.12.2025

Entero Therapeutics - rincian analitis lan metrik utama (ENTO)

- rega saiki lan proyeksi nilai saham:
Ringkesan analitik perusahaan:enterothera.com
Produk merek enterothera.com

Entero Therapeutics, Inc. (ENTO) focuses on developing innovative therapies for patients with gastrointestinal pathologies, making the annual trend of sales revenue over four quarters a key indicator of its asset commercialization. This metric measures the market consensus of the value of goods sold over a rolling year on a daily basis, allowing investors to strip away accounting distortions and objectively assess the real demand for the company's drugs.